Centro de Investigación en Ciencias de la Salud, Facultad de Ciencias de la Salud, Universidad Anáhuac, Mexico City, Mexico.
Neurophysiology Department, Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suarez", Mexico City, Mexico.
Brain Dev. 2024 Oct;46(9):294-301. doi: 10.1016/j.braindev.2024.07.002. Epub 2024 Jul 26.
This study aims to investigate the neuroprotective effects of cannabidiol (CBD) on neurodevelopmental impairments in rats subjected to neonatal hypoxia, specifically examining its potential to mitigate motor and sensory deficits without the confounding effects of ischemia.
Neonatal Sprague-Dawley rats were allocated to one of four groups: Control, Control-CBD, Hypoxia, and Hypoxia-CBD. Hypoxia was induced on postnatal days 0 and 1. CBD (50 mg/kg) was administered orally for 14 days starting at postnatal day 0. Neurodevelopmental outcomes were assessed using the Neurodevelopmental Reflex Testing in Neonatal Rat Pups scale and the Revised Neurobehavioral Severity Scale for rodents. Statistical analyses were conducted using two-way and one-way ANOVA, with Tukey's post-hoc tests for group comparisons.
Pup weights were recorded on specified postnatal days, with no significant differences observed across the groups (p = 0.1834). Significant neurological impairments due to hypoxia were noted in the Control group compared to the Hypoxia group, particularly in hindlimb grasping on postnatal day 3 (p = 0.0025), posture on postnatal day 12 (p = 0.0073), and in general balance and sound reflex on postnatal day 20 (p = 0.0016 and p = 0.0068, respectively). Additionally, a statistically significant improvement in posture was observed in the Hypoxia-CBD group compared to the Hypoxia group alone (p = 0.0024).
Our findings indicate that CBD possesses neuroprotective properties that significantly counteract the neurodevelopmental impairments induced by neonatal hypoxia in rats. This study not only supports the therapeutic potential of CBD in managing conditions characterized by neurodevelopmental challenges due to hypoxia but also underscores the necessity for further investigation into the specific molecular mechanisms driving CBD's neuroprotective effects. Further research is essential to explore CBD's clinical applications and its potential role in treating human neurodevelopmental disorders.
本研究旨在探讨大麻二酚 (CBD) 对新生大鼠缺氧后神经发育损伤的神经保护作用，具体研究其在减轻运动和感觉缺陷方面的潜力，同时避免缺血的混杂影响。
将新生 Sprague-Dawley 大鼠分为四组：对照组、对照组加 CBD、缺氧组和缺氧加 CBD 组。在出生后第 0 天和第 1 天诱导缺氧。从出生后第 0 天开始，每天口服 CBD（50mg/kg），共 14 天。使用新生大鼠神经发育反射测试量表和啮齿动物修订神经行为严重程度量表评估神经发育结局。使用双因素和单因素方差分析进行统计分析，并进行组间 Tukey 事后检验。
在特定的出生后天数记录了幼鼠体重，各组之间没有观察到显著差异（p=0.1834）。与缺氧组相比，对照组存在明显的因缺氧导致的神经功能障碍，尤其是在第 3 天的后肢抓握（p=0.0025）、第 12 天的姿势（p=0.0073）和第 20 天的一般平衡和声音反射（p=0.0016 和 p=0.0068）。此外，与单独缺氧组相比，缺氧加 CBD 组的姿势有显著改善（p=0.0024）。
我们的研究结果表明，CBD 具有神经保护作用，可显著对抗新生大鼠缺氧引起的神经发育损伤。本研究不仅支持 CBD 在治疗因缺氧引起的神经发育挑战相关疾病方面的治疗潜力，还强调了进一步研究驱动 CBD 神经保护作用的具体分子机制的必要性。进一步的研究对于探索 CBD 的临床应用及其在治疗人类神经发育障碍方面的潜在作用至关重要。
